A phase Ib/IIa study of INO-5401 in combination with REGN2810 a checkpoint inhibitor and INO-9012 in patients with newly-diagnosed glioblastoma multiforme (GBM)

Trial Profile

A phase Ib/IIa study of INO-5401 in combination with REGN2810 a checkpoint inhibitor and INO-9012 in patients with newly-diagnosed glioblastoma multiforme (GBM)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Cemiplimab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 Status changed from planning to recruiting, according to an Inovio Pharmaceuticals media release.
    • 10 May 2017 Inovio expects to begin enrollment in the second half of the year, according to a company media release.
    • 08 May 2017 According to an Inovio Pharmaceuticals media release, this study is expected to begin later 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top